首页> 外文期刊>Bone marrow transplantation >Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
【24h】

Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.

机译:氟达拉滨,环磷酰胺和马抗胸腺细胞球蛋白调节方案用于在非HEPA过滤室中进行的异基因外周血干细胞移植,适用于患有严重再生障碍性贫血的多次输血患者。

获取原文
获取原文并翻译 | 示例
           

摘要

Multiply transfused patients of severe aplastic anemia are at increased risk of graft rejection. Five such patients underwent peripheral blood stem cell transplantation from HLA-identical siblings with a fludarabine-based protocol. The conditioning consisted of fludarabine 30 mg/m(2)/day x 6 days, cyclophosphamide 60 mg/kg/day x 2 days and horse antithymocyte globulin (ATG) x 4 days. Two different ATG preparations were used: ATGAM (dose 30 mg/kg/day x 4 days) or Thymogam (dose 40 mg/kg/day x 4 days). Engraftment: median time to absolute neutrophil count (ANC) >0.5 x 10(9)/l was 11 days (range: 8-17) and median time to platelet count >20 x 10(9)/l was 11 days (range: 9-17). At a median follow-up of 171 days (range: 47-389), there has been no graft rejection and all patients are in complete remission. Acute GVHD (grade 1) occurred in one patient only. Chronic GVHD developed in two patients (extensive in one and limited in another). The transplants were performed in non-HEPA filter rooms. In only one patient, systemic antifungal therapy (voriconazole) was used. The use of Thymogam brand of ATG for conditioning is being reported for the first time. Our experience suggests that this fludarabine-based protocol allows rapid sustained engraftment in high-risk patients without significant immediate toxicity.
机译:重症再生障碍性贫血多次输血患者的移植排斥风险增加。五名此类患者接受了基于氟达拉滨的方案,从与HLA相同的兄弟姐妹进行了外周血干细胞移植。条件包括氟达拉滨30 mg / m(2)/天x 6天,环磷酰胺60 mg / kg /天x 2天和马抗胸腺细胞球蛋白(ATG)x 4天。使用了两种不同的ATG制剂:ATGAM(剂量为30 mg / kg /天x 4天)或Thymogam(剂量为40 mg / kg /天x 4天)。植入:中性粒细胞绝对计数(ANC)的中位数时间> 0.5 x 10(9)/ l为11天(范围:8-17),中位数至血小板计数> 20 x 10(9)/ l的中位数时间为11天(范围:9-17)。中位随访171天(范围:47-389),无移植物排斥反应,所有患者均已完全缓解。仅有一名患者发生了急性GVHD(1级)。两名患者发生了慢性GVHD(一名患者广泛,另一名患者有限)。移植在非HEPA过滤室中进行。仅一名患者使用全身抗真菌治疗(伏立康唑)。首次报道将ATG的Thymogam品牌用于调理。我们的经验表明,这种基于氟达拉滨的方案可在高危患者中快速持续植入,而无明显的即时毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号